NZ552580A - Her2 antibody composition - Google Patents

Her2 antibody composition

Info

Publication number
NZ552580A
NZ552580A NZ552580A NZ55258005A NZ552580A NZ 552580 A NZ552580 A NZ 552580A NZ 552580 A NZ552580 A NZ 552580A NZ 55258005 A NZ55258005 A NZ 55258005A NZ 552580 A NZ552580 A NZ 552580A
Authority
NZ
New Zealand
Prior art keywords
antibody
her2
antibodies
amino acid
composition
Prior art date
Application number
NZ552580A
Other languages
English (en)
Inventor
Yung-Hsiang Kao
Martin Vanderlaan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ552580A publication Critical patent/NZ552580A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ552580A 2004-07-22 2005-07-15 Her2 antibody composition NZ552580A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020204P 2004-07-22 2004-07-22
PCT/US2005/025084 WO2006033700A2 (en) 2004-07-22 2005-07-15 Her2 antibody composition

Publications (1)

Publication Number Publication Date
NZ552580A true NZ552580A (en) 2009-08-28

Family

ID=36090425

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552580A NZ552580A (en) 2004-07-22 2005-07-15 Her2 antibody composition

Country Status (36)

Country Link
US (3) US7560111B2 (OSRAM)
EP (1) EP1771482B1 (OSRAM)
JP (7) JP2008507520A (OSRAM)
KR (14) KR20190126461A (OSRAM)
CN (1) CN101023100B (OSRAM)
AR (2) AR050353A1 (OSRAM)
AU (1) AU2005287404B2 (OSRAM)
BR (1) BRPI0513681A (OSRAM)
CA (1) CA2574821C (OSRAM)
CO (1) CO5720212A1 (OSRAM)
CR (1) CR8932A (OSRAM)
DK (1) DK1771482T3 (OSRAM)
EC (1) ECSP077261A (OSRAM)
ES (1) ES2521140T3 (OSRAM)
GT (1) GT200500199A (OSRAM)
HR (1) HRP20141111T1 (OSRAM)
IL (1) IL180608A0 (OSRAM)
JO (1) JO2984B1 (OSRAM)
MA (1) MA28784B1 (OSRAM)
MX (1) MX2007000723A (OSRAM)
MY (1) MY169272A (OSRAM)
NO (1) NO341293B1 (OSRAM)
NZ (1) NZ552580A (OSRAM)
PA (1) PA8639701A1 (OSRAM)
PE (1) PE20060552A1 (OSRAM)
PL (1) PL1771482T3 (OSRAM)
PT (1) PT1771482E (OSRAM)
RS (1) RS53594B1 (OSRAM)
RU (1) RU2361880C2 (OSRAM)
SI (1) SI1771482T1 (OSRAM)
SV (1) SV2006002174A (OSRAM)
TN (1) TNSN07020A1 (OSRAM)
TW (1) TWI369992B (OSRAM)
UA (1) UA90480C2 (OSRAM)
WO (1) WO2006033700A2 (OSRAM)
ZA (1) ZA200701234B (OSRAM)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20190126461A (ko) 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
EP2028193B1 (en) 2005-01-05 2012-03-07 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) * 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
EA013617B1 (ru) 2005-02-24 2010-06-30 Амген Инк. Мутации рецептора эпидермального фактора роста
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2573114B1 (en) 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2007213791A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
SG170110A1 (en) * 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
EP2032159B1 (en) * 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008140603A2 (en) * 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
KR20150039212A (ko) 2007-03-02 2015-04-09 제넨테크, 인크. 낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
PT2182948E (pt) * 2007-07-24 2013-04-30 Novartis Ag Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
RU2370280C2 (ru) * 2007-10-08 2009-10-20 Институт физико-химической биологии им. А.Н.Белозерского СПОСОБ СУПЕРПРОДУКЦИИ В РАСТЕНИИ АНТИТЕЛ ПРОТИВ ОНКОГЕНА HER2/neu
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0906309A2 (pt) * 2008-04-02 2020-05-26 Macrogenics, Inc Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
CA2779436A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
CA2751730A1 (en) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
WO2010099186A1 (en) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
US8401035B2 (en) * 2009-07-14 2013-03-19 Level 3 Communications, Llc One way SRS information transmission method
US8064431B2 (en) * 2009-07-14 2011-11-22 Level 3 Communications, Llc One way information transmission method
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
RU2425840C1 (ru) * 2010-04-09 2011-08-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") АНТИТЕЛО, СПЕЦИФИЧЕСКИ ВЗАИМОДЕЙСТВУЮЩЕЕ С ОНКОБЕЛКОМ HER2/neu
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2558501B1 (en) 2010-04-15 2016-09-07 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
EP2568976B1 (en) 2010-05-10 2015-09-30 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
EP2825197B1 (en) * 2012-03-16 2018-06-06 Covagen AG Novel binding molecules with antitumoral activity
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
ES2546105T3 (es) 2012-04-17 2015-09-18 Arsanis Biosciences Gmbh Anticuerpo de reacción cruzada contra Staphylococcus aureus
ES2431914B2 (es) * 2012-04-27 2014-07-24 Universidad De Cádiz Anticuerpo monoclonal humano ANTI-HER2
RU2014149681A (ru) * 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг Антитела с множественной специфичностью
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
KR20200143502A (ko) 2012-08-13 2020-12-23 제넨테크, 인크. 항-jagged 항체 및 사용 방법
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
EA201591643A1 (ru) 2013-04-16 2016-02-29 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
KR101453462B1 (ko) * 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
CA2930307A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
SI3480215T1 (sl) 2013-11-19 2021-12-31 Remegen, Ltd. Protitelo proti-HER2 in njegov konjugat
EP3074424B1 (en) 2013-11-27 2025-02-12 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
EP3083696B1 (en) 2013-12-20 2018-02-14 F.Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
KR102088169B1 (ko) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
SMT202500030T1 (it) * 2014-01-31 2025-03-12 Daiichi Sankyo Co Ltd Coniugato anticorpo anti-her2-farmaco
US20170002046A1 (en) 2014-03-11 2017-01-05 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
PL3604333T3 (pl) 2014-03-11 2021-11-08 Molecular Templates, Inc. Białka zawierające regiony efektorowe podjednostki a toksyny shiga proksymalnie do końca aminowego oraz celujące w komórki regiony wiążące typu immunoglobuliny zdolne do swoistego wiązania cd38
ES2800674T3 (es) * 2014-03-21 2021-01-04 X Body Inc Polipéptidos biespecíficos de unión a antígeno
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
CN107074945B (zh) 2014-05-27 2021-08-24 中央研究院 增进抗体功效的通用糖型的组合物及方法
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
KR101608301B1 (ko) 2014-08-22 2016-04-12 앱클론(주) Her2에 특이적으로 결합하는 항체
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
SG11201701623UA (en) * 2014-09-12 2017-03-30 Genentech Inc Anti-her2 antibodies and immunoconjugates
KR20170055521A (ko) 2014-09-17 2017-05-19 제넨테크, 인크. 항-her2 항체를 포함하는 면역콘주게이트
CN104225594B (zh) * 2014-09-23 2016-03-23 合肥瀚科迈博生物技术有限公司 抗her2人源化抗体及其相关的抗肿瘤组合物
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3226892A4 (en) 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
CN105985435B (zh) * 2015-01-30 2019-10-15 嘉和生物药业有限公司 全人源her2抗体的突变抗体及其编码基因和应用
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20180100026A1 (en) * 2015-04-15 2018-04-12 California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
WO2016179707A1 (en) 2015-05-13 2016-11-17 Zymeworks Inc. Antigen-binding constructs targeting her2
HUE068105T2 (hu) 2015-05-30 2024-12-28 Hoffmann La Roche Eljárások korábban kezeletlen her2-pozitív metasztatikus emlõrák kezelésére
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
CN107847481A (zh) 2015-06-03 2018-03-27 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂
WO2017002776A1 (ja) 2015-06-29 2017-01-05 第一三共株式会社 抗体－薬物コンジュゲートの選択的製造方法
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
CN105132357B (zh) * 2015-07-29 2019-12-06 苏州诺普再生医学有限公司 一种用于表皮细胞培养的无血清培养体系
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102645625B1 (ko) 2015-09-22 2024-03-07 제넨테크, 인크. Fc-함유 단백질의 발현
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
BR112018009129A2 (pt) * 2015-11-04 2019-02-26 J. PRICEMAN Saul receptores de antígeno quimérico que visam her2
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TWI778491B (zh) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
RU2648161C2 (ru) * 2016-04-01 2018-03-22 Юрий Леонидович Дорохов Способ получения антитела, специфически связывающего домен димеризации экзоклеточной части онкобелка HER2/neu, в растении, антитело, полученное этим способом, и его применение
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
KR101923624B1 (ko) 2016-07-28 2018-11-30 고려대학교 산학협력단 암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR20190075114A (ko) 2016-11-04 2019-06-28 제넨테크, 인크. Her2-양성 유방암의 치료
KR101923641B1 (ko) 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
TW202508642A (zh) 2016-12-12 2025-03-01 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
KR102313262B1 (ko) 2016-12-28 2021-10-14 제넨테크, 인크. 진행성 her2 발현 암의 치료
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
US10849849B2 (en) 2017-01-17 2020-12-01 Genentech Inc. Subcutaneous HER2 antibody formulations
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
EP3572429A4 (en) 2017-01-23 2021-04-07 Suzhou Alphamab Co., Ltd POLYPEPTIDE OR COMPOSITE BINDER PD-L1
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907646YA (en) * 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
ES2969041T3 (es) 2017-03-02 2024-05-16 Genentech Inc Tratamiento adyuvante del cáncer de mama positivo para HER2
US11207420B2 (en) 2017-04-19 2021-12-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Cytotoxin and conjugate, uses of same and preparation method therefor
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
TW202532103A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3688023B1 (en) 2017-09-25 2025-08-27 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. Methods and compositions for cancer treatment
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12116417B2 (en) * 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN113683622B (zh) 2017-12-15 2025-02-18 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
US20210221894A1 (en) * 2018-04-03 2021-07-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
CN111741979B (zh) 2018-04-13 2024-07-02 豪夫迈·罗氏有限公司 包含4-1BBL的Her2靶向性抗原结合分子
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2019232323A1 (en) * 2018-05-31 2019-12-05 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
US12358999B2 (en) 2018-07-27 2025-07-15 Daiichi Sankyo Company, Limited Protein recognizing drug moiety of antibody-drug conjugate
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
SG11202100663VA (en) 2018-08-01 2021-02-25 Cephalon Inc Anti-cxcr2 antibodies and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
CN112955137B (zh) 2018-09-10 2025-05-13 米拉蒂治疗股份有限公司 组合疗法
LT3856774T (lt) 2018-10-15 2023-03-10 F. Hoffmann-La Roche Ag Liekamojo krūties vėžio gydymo trastuzumabo emtanzinu būdai
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
CA3081503A1 (en) 2019-12-06 2021-06-06 Zymeworks Inc. Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.
CA3188134A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024522082A (ja) 2021-05-19 2024-06-11 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド 窒素含有化合物、それを含む複合体及びその使用
EP4386006A1 (en) 2021-07-05 2024-06-19 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Antibody-drug conjugate and application thereof
EP4374879A1 (en) 2021-07-22 2024-05-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CA3252323A1 (en) * 2022-02-19 2023-08-24 Salvitus, Inc. PROBIOTIC VACCINES AND ASSOCIATED METHODS OF USE
AU2023350248A1 (en) 2022-09-30 2025-04-17 Shanghai De Novo Pharmatech Co., Ltd. Benzazepine derivative, conjugate containing same, and use thereof
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
WO2024173565A2 (en) * 2023-02-14 2024-08-22 New York University Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
WO2025019254A1 (en) 2023-07-14 2025-01-23 Guardant Health, Inc. Classification of breast tumors using dna methylation from liquid biopsy

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
KR100269879B1 (ko) 1992-06-30 2000-10-16 폴 에이치. 피셔 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
DK0730740T3 (da) 1993-11-23 1998-09-28 Genentech Inc Kinasereceptoraktiveringsassay
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CN100415772C (zh) 1996-10-18 2008-09-03 基因技术股份有限公司 抗ErbB2抗体
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ATE398464T1 (de) 1998-03-27 2008-07-15 Genentech Inc Synergie zwischen apo-2 ligand und antikörper gegen her-2
DK1308455T3 (da) 1998-05-06 2006-07-31 Genentech Inc Sammensætning omfattende anti-HER2-antistoffer
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
ES2320311T3 (es) 1999-05-14 2009-05-21 Genentech, Inc. Tratamiento con anticuerpos anti-erbb2.
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
MXPA01013458A (es) 1999-06-25 2002-07-30 Genentech Inc Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1189634B1 (en) 1999-06-25 2007-02-28 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
WO2001001748A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
HK1048260B (zh) 1999-08-27 2009-03-13 杰南技术公司 用於抗erbb2抗体治疗的制剂
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
MXPA02011379A (es) 2000-05-19 2003-06-06 Genentech Inc Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
JP2005522514A (ja) * 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
AU2002333006A1 (en) * 2002-09-19 2004-04-08 Gilberto De Nucci Pharmaceutical composition comprising carriers for products
US20040258685A1 (en) 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
WO2005099756A2 (en) * 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20190126461A (ko) * 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) * 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) * 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20090019890A (ko) * 2006-06-05 2009-02-25 제넨테크, 인크. Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
KR20150039212A (ko) 2007-03-02 2015-04-09 제넨테크, 인크. 낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático

Also Published As

Publication number Publication date
CO5720212A1 (es) 2007-01-31
UA90480C2 (uk) 2010-05-11
JP2020079254A (ja) 2020-05-28
US20060018899A1 (en) 2006-01-26
MY169272A (en) 2019-03-21
WO2006033700A2 (en) 2006-03-30
AR050353A1 (es) 2006-10-18
PA8639701A1 (es) 2006-07-03
US20090285837A1 (en) 2009-11-19
KR20140032004A (ko) 2014-03-13
KR20130079648A (ko) 2013-07-10
US7560111B2 (en) 2009-07-14
RU2007106725A (ru) 2008-08-27
US7879325B2 (en) 2011-02-01
CA2574821C (en) 2013-07-09
HRP20141111T1 (hr) 2015-01-02
US8241630B2 (en) 2012-08-14
JP2008507520A (ja) 2008-03-13
JO2984B1 (ar) 2016-09-05
RS53594B1 (sr) 2015-02-27
RU2361880C2 (ru) 2009-07-20
KR20150043558A (ko) 2015-04-22
US20110117097A1 (en) 2011-05-19
EP1771482A2 (en) 2007-04-11
AR111209A2 (es) 2019-06-12
PT1771482E (pt) 2014-11-03
ECSP077261A (es) 2007-04-26
CN101023100B (zh) 2012-08-29
DK1771482T3 (da) 2014-10-20
MX2007000723A (es) 2007-03-12
ZA200701234B (en) 2008-12-31
SV2006002174A (es) 2006-03-06
KR20120068807A (ko) 2012-06-27
KR20190126461A (ko) 2019-11-11
KR20170054551A (ko) 2017-05-17
EP1771482B1 (en) 2014-08-20
AU2005287404B2 (en) 2009-05-07
BRPI0513681A (pt) 2008-05-13
KR20110050567A (ko) 2011-05-13
KR20100101023A (ko) 2010-09-15
JP2017141283A (ja) 2017-08-17
NO341293B1 (no) 2017-10-02
WO2006033700A3 (en) 2006-09-21
KR20160096228A (ko) 2016-08-12
AU2005287404A1 (en) 2006-03-30
KR20180004850A (ko) 2018-01-12
CN101023100A (zh) 2007-08-22
KR20180091967A (ko) 2018-08-16
MA28784B1 (fr) 2007-08-01
TNSN07020A1 (en) 2008-06-02
PE20060552A1 (es) 2006-09-06
CR8932A (es) 2008-04-25
KR20190035967A (ko) 2019-04-03
TW200616661A (en) 2006-06-01
NO20070989L (no) 2007-04-18
PL1771482T3 (pl) 2015-02-27
IL180608A0 (en) 2007-06-03
JP2016104760A (ja) 2016-06-09
HK1102599A1 (en) 2007-11-30
ES2521140T3 (es) 2014-11-12
KR20070038557A (ko) 2007-04-10
CA2574821A1 (en) 2006-03-30
KR20150140417A (ko) 2015-12-15
GT200500199A (es) 2007-03-23
TWI369992B (en) 2012-08-11
JP2018197258A (ja) 2018-12-13
JP2011173914A (ja) 2011-09-08
SI1771482T1 (sl) 2014-12-31
JP2014208685A (ja) 2014-11-06

Similar Documents

Publication Publication Date Title
US12110341B2 (en) Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
CA2574821C (en) Her2 antibody composition
HK1262585B (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
HK1262585A1 (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2016 BY THOMSON REUTERS

Effective date: 20150620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2017 BY THOMSON REUTERS

Effective date: 20160610

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2018 BY THOMSON REUTERS

Effective date: 20170621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY THOMSON REUTERS

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY THOMSON REUTERS

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2021 BY THOMSON REUTERS

Effective date: 20200622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2022 BY THOMSON REUTERS

Effective date: 20210604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2023 BY THOMSON REUTERS

Effective date: 20220603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2024 BY ANAQUA SERVICES

Effective date: 20230621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2025 BY ANAQUA SERVICES

Effective date: 20240619

EXPY Patent expired